BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 17509328)

  • 21. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder.
    Giannantoni A; Conte A; Proietti S; Giovannozzi S; Rossi A; Fabbrini G; Porena M; Berardelli A
    J Urol; 2011 Sep; 186(3):960-4. PubMed ID: 21791351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial.
    Ghei M; Maraj BH; Miller R; Nathan S; O'Sullivan C; Fowler CJ; Shah PJ; Malone-Lee J
    J Urol; 2005 Nov; 174(5):1873-7; discussion 1877. PubMed ID: 16217327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
    Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
    Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
    White WM; Pickens RB; Doggweiler R; Klein FA
    J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study.
    Ehren I; Volz D; Farrelly E; Berglund L; Brundin L; Hultling C; Lafolie P
    Scand J Urol Nephrol; 2007; 41(4):335-40. PubMed ID: 17763227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial.
    Dowson C; Sahai A; Watkins J; Dasgupta P; Khan MS
    Int J Clin Pract; 2011 Jun; 65(6):698-704. PubMed ID: 21564444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
    Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH
    Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
    Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
    J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
    Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
    Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.